Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 2Melanoma 2Uveal Melanoma 1Lung Neoplasms 1Lung Diseases 1Colorectal Neoplasms 1Carcinoma 1Bronchial Neoplasms 1Breast Neoplasms 1

Interventions

Carboplatin 9Pemetrexed 7osimertinib 5pembrolizumab 3entinostat 3durvalumab 3Radiosurgery 3Cisplatin 3Bevacizumab 3selpercatinib 2camrelizumab 2Paclitaxel 2Gemcitabine 2Erlotinib Hydrochloride 2Docetaxel 2trametinib 1sotorasib 1repotrectinib 1pralsetinib 1patritumab 1nazartinib 1napabucasin 1icotinib 1exemestane 1cobimetinib 1ceralasertib 1cemiplimab 1capmatinib 1atezolizumab 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bronchial Neoplasms × Toll-Like Receptor 1 × Thoracic × Clear all
NCT04614103 2026-04-15

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Iovance Biotherapeutics, Inc.

Phase 2 Recruiting
170 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡